Ann: SUDA Enters Agreement To Develop Cannabinoid Spray, page-99

kcl,

Again you miss the point, the trouble with SC is he over estimates his own ability, it was his timelines, his comparable table that has been missed time and time again.

His over estimations on a number of fronts is the reason that the sp has failed to react to deals which taken in isolation (forgetting previous statements / announcements) would have the sp flying.

Its time for him to go, the sp will only stagnate until he is gone imo.

As for hindsight - he has had many changes to see the errors in his ways and has failed to correct those errors and report what actually is happening

So you can say us negative posters are whingers but the sad fact you and the rest of the positive posters have come up short with your statements time and time again.

Then we have those trying to convince us that Stride and ZELDA are going to pay large monthly development payments (the claim being this is what SC told them at the AGM)

PERTH, AUSTRALIA – 17 November 2015:

SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it is on track with its business development goals to sign licensing deals in FY2015/16

From 2015 AGM

2015 Highlights| Progressing towards our BD goals
§ Meetings with approx 200 Pharma since start of outreach in March 2014 § Active discussions span in-house pipeline & applications of OroMist® technology
§ Over 30 companies at various stages of due diligence or term sheet negotiations
§ Potential for multiple licensing deals in FY2015/6 and beyond

From 2016 AGM

2016 Highlights| Achieving our BD goals
 Close to 60 pharma companies in active discussions
 Discussions on pipeline licensing & OroMist® applications  >25 pharma companies conducting due diligence and/or negotiating terms
 First ZolpiMist licensing agreement signed and more deals anticipated

From 2017 AGM

ZolpiMist deals in Europe and elsewhere ✓
Further partnering deals with SUDA’s other candidates ✓
Monetisation of ArTiMist ✓
Expansion of Pfizer collaboration ✓
More co-development partnerships ✓
Early sales success by ZolpiMist partners ✓
Approval of ZolpiMIst in Australia, China, LatAm and Europe


From 2018 AGM

•Two signed deals
•Strong interest from a number of Mid and Large Pharmaceutical companies
• Single and Multi territory deals
• Late stage negotiations at agreement stage
• Long term revenue through royalties